Biopharma patents in China: Litigation, licensing, and patent linkage
As the past two years have shown, the biopharmaceutical industry is more important than ever in producing drugs that improve and save lives. For U.S. biopharmaceutical companies, China continues to be an important market. Securing and enforcing intellectual property (IP) rights in China is critical for U.S. companies to succeed in this growing market and to recoup the tremendous investments in development of new medicines.
This recording of a program held on February 24, 2022 featured presentations by senior United States Patent and Trademark Office (USPTO) IP attorneys and seasoned practitioners with extensive China IP experience. View the full agenda here: https://bit.ly/3i86E5O